Skip to main content
. 2014 May;58(5):2856–2865. doi: 10.1128/AAC.02139-13

TABLE 2.

Significant steps in piperacillin-tazobactam population plasma PK model-building processa

Population model OFV ΔOFVb
Piperacillin
    V = θV · WT 1,125
    CL = θCL · WT 1,125
    CL = θCL · WT · (PMA/33)COVPMA 1,113 −12
    CL = θCL · WT · (SCR/0.5)COVSCR 1,106 −19
    CL = θCL · WT · (SCR/0.5)COVSCR · COVGENTGENT 1,093 −13
    CL = θCL · WT · (SCR/0.5)COVSCR · COVGENTGENT · (PMA/33)COVPMA 1,092 −1
Tazobactam
    V = θV · WT 509
    CL = θCL · WT 509
    CL = θCL · WT · (PMA/33)COVPMA 491 −18
    CL = θCL · WT · (SCR/0.5)COVSCR 491 −18
    CL = θCL · WT · (SCR/0.5)COVSCR · COVGENTGENT 480 −11
    CL = θCL · WT · (SCR/0.5)COVSCR · COVGENTGENT · (PMA/33)COVPMA 470 −10
a

WT, actual body weight (kg); SCR, serum creatinine (mg/dl); GENT = 1 if gentamicin was given concurrently with piperacillin-tazobactam, and GENT = 0 if there was no concurrent therapy; PMA, postmenstrual age (weeks); OFV, objective function value.

b

For multivariable models, the change in OFV is relative to the prior model.